Ketotifen Hasco

Ketotifen, the active ingredient in Ketotifen Hasco, is an antihistamine (H1 receptor antagonist) and mast cell stabilizer presented as an oral tablet for oral use. It treats allergic rhinitis, allergic conjunctivitis and is employed for asthma prophylaxis in both adults and children.

GNH USA supplies Ketotifen Hasco as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Ketotifen is used to manage allergic conditions by stabilizing mast cells and blocking histamine receptors.

- Allergic rhinitis: reduces nasal congestion, sneezing and itching. - Allergic conjunctivitis: alleviates eye itching, redness and watery discharge. - Asthma prophylaxis: helps prevent bronchial hyperreactivity and asthma attacks.

Ketotifen may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness or sedation. - Dry mouth. - Headache. - Nausea or gastrointestinal discomfort. - Increased appetite or weight gain.

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome. - Anaphylactic reactions. - Hepatotoxicity indicated by elevated liver enzymes. - Blood dyscrasias including neutropenia or agranulocytosis.

When using Ketotifen, certain precautions should be observed to ensure safety.

- Pregnancy: use only if clearly needed; consult a healthcare professional. - Breastfeeding: assess risk versus benefit before use. - Driving or operating machinery: avoid if experiencing drowsiness. - Hepatic impairment: monitor liver function regularly. - Concomitant CNS depressants: use with caution as sedation may increase. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ketotifen can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Other antihistamines or sedating drugs: may intensify drowsiness. - Monoamine oxidase inhibitors (MAOIs): risk of additive antihistaminic effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase ketotifen plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce ketotifen effectiveness. - Theophylline: monitor for potential additive bronchodilator effects.